Nature Biotechnology’s academic spinouts 2022

Nature Biotechnology

volume 41pages 1669–1678 (2023)Cite this article

Nature Biotechnology’s annual survey highlights academic start ups that are, among other things, correcting misfolded or disordered proteins, creating second-generation GPCR agonists, building a new gene delivery platform and mining cancer genomes for novel targets.

As in previous years of our survey, we focus on R&D-intensive startups spun out from academic institutions (Table 1). These were first identified as having raised a series A financing in 2021. Our editors then assessed publicly available information about each firm’s research to select those that appear below. (Some firms were selected but not included because they were still in ‘stealth mode’ or declined to be interviewed.)

Table 1 The class of 2022: NBT’s academic spinouts

This is a preview of subscription content, access via your institution

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

24,99 € / 30 days

cancel any time

Subscribe to this journal

Receive 12 print issues and online access

214,86 € per year

only 17,91 € per issue

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. Philadelphia, PA, USA

    Michael Eisenstein

  2. Portland, ME, USA

    Charles Schmidt

  3. Pasadena, CA, USA

    Laura DeFrancesco

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eisenstein, M., Schmidt, C. & DeFrancesco, L. Nature Biotechnology’s academic spinouts 2022.
Nat Biotechnol 41, 1669–1678 (2023). https://doi.org/10.1038/s41587-023-02023-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-023-02023-z

Read More